← Back to headlines
.png%3Fwidth%3D1200%26auto%3Dwebp%26trim%3D73%252C0%252C139%252C0&w=828&q=75&output=webp&default=1)
Bristol-Myers Squibb Raises 2026 Guidance, Milvexian AFib Readout Shifts
Bristol-Myers Squibb has increased its 2026 financial guidance, projecting 20-25% growth for Eliquis, while the readout for its milvexian AFib drug has been postponed to Q1 2027.
30 Jul, 19:25 — 30 Jul, 19:25
Sources
Showing 1 of 1 sources
Related Stories
Oldest Known Plague Outbreak Discovered in Siberia Dating Back 5,500 Years
just now
New Research Suggests Deep Breathing May Increase Risky Decision-Making
32m ago
Bryan Johnson's Girlfriend Undertakes 'World First' Menstrual Health Research
35m ago
Cyclospora's Complex Biology Contributes to Persistent Infections
58m ago